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SHORT REPORT
Case-control study of the association between kava use and
ischaemic heart disease in Aboriginal communities in
eastern Arnhem Land (Northern Territory) Australia
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K
ava, (Piper methysticum Forst. f., ‘‘Intoxicating pepper’’),
is a consciousness-changing muscle relaxant consumed
in the Pacific islands and, since 1982, by indigenous
Australians in eastern Arnhem Land (Northern Territory, NT)
using dried powder imported from Fiji or Tonga.1 Very heavy
use was widespread in Arnhem Land during the 1990s.1
Circumstantial evidence suggests that kava consumption is
associated with ischaemic heart disease (IHD) and sudden
cardiac deaths among, particularly, young Aboriginal sports-
men in this population.2
METHODS
In a case-control study, cases comprised 83 people admitted
to hospital for the first time during 1992–1997 from the
region with a medical officer’s confirmed diagnosis of IHD
(ICD9 Codes 4100–4149). Of these, 25 were admitted on
more than one occasion. Up to four randomly selected
controls (n = 302) were matched with each case for age, sex,
and home locality. NT registries indicated that a further 20
people with no record of hospital admission died with IHD
during 1992–1997. These were matched with 75 controls.
Comprehensive data were not available to identify IHD
morbidity before 1992.
Methods to measure exposure to kava use, alcohol,
tobacco, petrol sniffing, cannabis use, and other possible
confounding factors, data analysis techniques, and ethics
approvals have been described elsewhere.3
RESULTS
Adjusting for confounders, odds ratios (OR) for kava use
before or during 1992–97 changed from 1.41 (95% CI 0.73 to
2.73, p = 0.303) to 1.51 (0.75 to 3.05, p = 0.247) (table 1).
There was no residual confounding effect of age in the
multivariate model (OR = 1.50, 0.74 to 3.04), (x2 = 0.23,
likelihood ratio test, p = 0.635). There was no association
with kava use in just those communities where kava had
been used for up to 15 years (adjusted OR = 1.75, 0.82 to
3.74, p = 0.140) or when those admitted on more than one
occasion (n = 25) were compared with their matched
controls (n = 132) (adjusted OR = 2.24, 0.65 to 7.68,
p = 0.191).
Twenty who died from IHD without hospital admission
and 75 matched controls were combined with 83 known
admissions and 302 matched controls. No association with
kava use was found (adjusted OR = 1.44, 0.78 to 2.66,
p = 0.245) so the results of the analysis of IHD admissions
alone were probably not influenced by survival bias.
While the expected association between IHD and tobacco
use was not found in the univariate analysis (table 1), it
appeared when 36 cases were compared with 158 controls
who had no record of kava, alcohol, cannabis, or petrol use
(OR = 3.96, 1.08 to 14.49, p = 0.021).
DISCUSSION
There was no clear evidence for an association between kava
use and IHD. Twice the risk of IHD was the smallest
detectable risk (80% power, 95%CI) in this study. Further
research is warranted given the non-significant tendency for
approximately 50% increased risk of IHD found in kava users
and given the lack of information about kava’s effects.
It is not known if an association between kava use and IHD
would develop in time. Results of a recent cross sectional study
in one community did not support this, as serum concentra-
tions of markers of thrombolytic processes and carotid arterial
wall thicknesses were no different in those who had used kava
for 1–18 years (median 12 years) when compared with non-
users.1 Moreover, kava has been used for centuries by Pacific
peoples with no evidence for an association with heart disease.
In Aboriginal kava drinkers, disrupted lipid profiles and
tendencies for raised HDL-cholesterol and LDL-cholesterol,1
are not clearly indicative of increased atheroma risk.
Aboriginal sportsmen who may already have established
IHD may be at higher risk of cardiac events if heavy kava use
accompanies vigorous exercise. Heavy kava users may
become dehydrated and myocardial ischaemia and sudden
cardiac death are possible attributable to abnormal coagula-
tion with increased thrombosis and/or arrhythmias.2
Acute effects of kava may also be mediated by neurological
mechanisms. Large doses of kava pyrones can lead to
abnormal atrioventricular function, consistent with kava’s well
known muscle relaxing properties.4 Actions of kava pyrones
on voltage gated ion channels, with antagonistic effects on
Na+ and Ca2+ currents and modulation of K+ currents, are of
importance for their mood stabilisation properties and these
cellular actions show a large overlap with the actions of
established mood stabilising drugs.4 Antipsychotic drugs
prolong QTc interval and bind to the potassium rectifier
channel, and their use may be associated with torsades de
pointes and sudden cardiac death.5 Similar outcomes with
kava use should be considered especially in Aboriginal kava
drinkers who may already suffer abnormalities in cardiac
output or effective mechanical performance.
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Table 1 Odds ratios and 95% confidence intervals for the association between IHD and kava use and other substance use
Crude odds ratios for the association between IHD and kava use and other substance use
‘‘a’’ = reference category Cases Controls OR 95%CI p Value*
Kava—use before or during
admission period 1992–97
Yes 33 103 1.41 0.73 2.73 0.303
a No 50 199 1.00
Kava—level of use
a None 50 199 1.00
1 night/week for a few hours 4 6 3.43 0.76 15.58
.1 night/week for a few hours 7 13 2.17 0.75 6.30
About 2 nights a week 6 17 1.61 0.57 4.56 0.342
Drink kava during the day as well as at night 2 14 0.63 0.12 3.29
Sometimes drink for 24 hour sessions 13 48 1.11 0.45 2.75
Alcohol—use before or during
admission period 1992–97
Yes 41 143 1.21 0.61 2.39 0.590
a No 40 157 1.00
Alcohol—level of use
a None 40 157 1.00
Light 5 15 1.91 0.54 6.73
Moderate 6 31 0.86 0.29 2.51 0.679
Heavy 26 92 1.26 0.60 2.64
Tobacco—use before or during
admission period 1992–97
Yes 71 252 1.29 0.61 2.70 0.500
a No 11 50 1.00
Tobacco—level of use
a None 11 50 1.00
Up to 15 cigarettes a day 5 8 3.03 0.72 12.70
From 15 up to 25 cigarettes a day 2 33 0.26 0.05 1.29
25 cigarettes a day 36 105 1.80 0.80 4.06 0.019
More than 25 cigarettes a day 26 99 1.14 0.49 2.64
Petrol—use before or during
admission period 1992–97
Yes 5 14 1.32 0.41 4.22 0.648
a No 76 279 1.00
Cannabis—use before or during
admission period 1992–97
Yes 5 33 0.46 0.16 1.35 0.137
a No 74 257 1.00
Odds ratios for the association between IHD and kava use adjusted for a history of alcohol and tobacco use, petrol sniffing and body size
‘‘a’’ = reference category Cases Controls OR 95%CI p Value*
Kava—use before or during
admission period 1992–97
Yes 33 103 1.51 0.75 3.05 0.247
a No 50 199 1.00
Kava—level of use
a None 50 199 1.00
1 night/week for a few hours 4 6 3.48 0.74 16.30
.1 night/week for a few hours 7 13 1.64 0.48 5.55
about 2 nights a week 6 17 1.83 0.62 5.44 0.469
Drink kava during the day as well as at night 2 14 0.63 0.12 3.38
Sometimes drink for 24 hour sessions 13 48 1.30 0.51 3.35
*Likelihood ratio test.
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